{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:30Z","timestamp":1783075950462,"version":"3.54.6"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40263-020-00768-8","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T06:29:34Z","timestamp":1605680974000},"page":"1253-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-5734","authenticated-orcid":false,"given":"Benjamin","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-2908","authenticated-orcid":false,"given":"Sander","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-0157","authenticated-orcid":false,"given":"Rob","family":"Zuiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-7730","authenticated-orcid":false,"given":"Muriel","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0788-3788","authenticated-orcid":false,"given":"Clemens","family":"Muehlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-5817","authenticated-orcid":false,"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"issue":"3","key":"768_CR1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.117.241596","volume":"362","author":"A Treiber","year":"2017","unstructured":"Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, et al. The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468. J Pharmacol Exp Ther. 2017;362(3):489\u2013503.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"768_CR2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/1389200220666190206141814","volume":"20","author":"C Muehlan","year":"2019","unstructured":"Muehlan C, Fischer H, Zimmer D, Aissaoui H, Grimont J, Boss C, et al. Metabolism of the dual orexin receptor antagonist ACT-541468, based on microtracer\/accelerator mass spectrometry. Curr Drug Metab. 2019;20(4):254\u201365.","journal-title":"Curr Drug Metab"},{"issue":"5","key":"768_CR3","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/cpt.1046","volume":"104","author":"C Muehlan","year":"2018","unstructured":"Muehlan C, Heuberger J, Juif PE, Croft M, van Gerven J, Dingemanse J. Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study. Clin Pharmacol Ther. 2018;104(5):1022\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"768_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13370","author":"I Zenklusen","year":"2020","unstructured":"Zenklusen I, Muehlan C, Ulc I, Liska J, Dingemanse J. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin. Clin Exp Pharmacol Physiol. 2020. https:\/\/doi.org\/10.1111\/1440-1681.13370.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"2","key":"768_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00228-018-2559-5","volume":"75","author":"ML Boof","year":"2019","unstructured":"Boof ML, Alatrach A, Ufer M, Dingemanse J. Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. Eur J Clin Pharmacol. 2019;75(2):195\u2013205.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"768_CR6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuron.2005.03.010","volume":"46","author":"T Sakurai","year":"2005","unstructured":"Sakurai T, Nagata R, Yamanaka A, Kawamura H, Tsujino N, Muraki Y, et al. Input of orexin\/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron. 2005;46(2):297\u2013308.","journal-title":"Neuron"},{"issue":"3","key":"768_CR7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.5665\/sleep.5536","volume":"39","author":"PL Tannenbaum","year":"2016","unstructured":"Tannenbaum PL, Tye SJ, Stevens J, Gotter AL, Fox SV, Savitz AT, et al. Inhibition of orexin signaling promotes sleep yet preserves salient arousability in monkeys. Sleep. 2016;39(3):603\u201312.","journal-title":"Sleep"},{"issue":"8","key":"768_CR8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/hup.980","volume":"23","author":"S Otmani","year":"2008","unstructured":"Otmani S, Demazieres A, Staner C, Jacob N, Nir T, Zisapel N, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol. 2008;23(8):693\u2013705.","journal-title":"Hum Psychopharmacol"},{"issue":"3","key":"768_CR9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.25680","volume":"87","author":"Y Dauvilliers","year":"2020","unstructured":"Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Seboek Kinter D, Pain S, et al. Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Ann Neurol. 2020;87(3):347\u201356.","journal-title":"Ann Neurol"},{"issue":"21","key":"768_CR10","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","volume":"94","author":"G Zammit","year":"2020","unstructured":"Zammit G, Dauvilliers Y, Pain S, Sebok Kinter D, Mansour Y, Kunz D. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 2020;94(21):e2222\u201332.","journal-title":"Neurology."},{"issue":"3","key":"768_CR11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/0269881119882854","volume":"34","author":"C Muehlan","year":"2020","unstructured":"Muehlan C, Boehler M, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. J Psychopharmacol. 2020;34(3):326\u201335.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"768_CR12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.euroneuro.2019.05.009","volume":"29","author":"C Muehlan","year":"2019","unstructured":"Muehlan C, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. Eur Neuropsychopharmacol. 2019;29(7):847\u201357.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"768_CR13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1517\/17425255.3.5.719","volume":"3","author":"GR Jang","year":"2007","unstructured":"Jang GR, Harris RZ. Drug interactions involving ethanol and alcoholic beverages. Expert Opin Drug Metab Toxicol. 2007;3(5):719\u201331.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"3","key":"768_CR14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2125.2010.03846.x","volume":"71","author":"RW Zoethout","year":"2011","unstructured":"Zoethout RW, Delgado WL, Ippel AE, Dahan A, van Gerven JM. Functional biomarkers for the acute effects of alcohol on the central nervous system in healthy volunteers. Br J Clin Pharmacol. 2011;71(3):331\u201350.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"768_CR15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/00023210-200317070-00004","volume":"17","author":"LM Hesse","year":"2003","unstructured":"Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs. 2003;17(7):513\u201332.","journal-title":"CNS Drugs"},{"issue":"4","key":"768_CR16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/BF02244655","volume":"110","author":"AL van Steveninck","year":"1993","unstructured":"van Steveninck AL, Gieschke R, Schoemaker HC, Pieters MS, Kroon JM, Breimer DD, et al. Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. Psychopharmacology. 1993;110(4):471\u20138.","journal-title":"Psychopharmacology"},{"issue":"6","key":"768_CR17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1365-2125.1996.38514.x","volume":"41","author":"AL van Steveninck","year":"1996","unstructured":"van Steveninck AL, Gieschke R, Schoemaker RC, Roncari G, Tuk B, Pieters MS, et al. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol. 1996;41(6):565\u201373.","journal-title":"Br J Clin Pharmacol"},{"key":"768_CR18","first-page":"233","volume":"8","author":"LE Hollister","year":"1990","unstructured":"Hollister LE. Interactions between alcohol and benzodiazepines. Recent Dev Alcohol. 1990;8:233\u20139.","journal-title":"Recent Dev Alcohol"},{"issue":"1","key":"768_CR19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2005.01.006","volume":"107","author":"GR Siggins","year":"2005","unstructured":"Siggins GR, Roberto M, Nie Z. The tipsy terminal: presynaptic effects of ethanol. Pharmacol Ther. 2005;107(1):80\u201398.","journal-title":"Pharmacol Ther"},{"key":"768_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-642-28720-6_143","volume":"13","author":"DM Lovinger","year":"2013","unstructured":"Lovinger DM, Roberto M. Synaptic effects induced by alcohol. Curr Top Behav Neurosci. 2013;13:31\u201386.","journal-title":"Curr Top Behav Neurosci."},{"issue":"2","key":"768_CR21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/sleep\/21.2.178","volume":"21","author":"EO Johnson","year":"1998","unstructured":"Johnson EO, Roehrs T, Roth T, Breslau N. Epidemiology of alcohol and medication as aids to sleep in early adulthood. Sleep. 1998;21(2):178\u201386.","journal-title":"Sleep"},{"issue":"Suppl 2","key":"768_CR22","first-page":"S347","volume":"22","author":"S Ancoli-Israel","year":"1999","unstructured":"Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep. 1999;22(Suppl 2):S347\u201353.","journal-title":"Sleep."},{"issue":"1","key":"768_CR23","first-page":"1","volume":"26","author":"MD Stein","year":"2005","unstructured":"Stein MD, Friedmann PD. Disturbed sleep and its relationship to alcohol use. Subst Abuse. 2005;26(1):1\u201313.","journal-title":"Subst Abuse"},{"issue":"3","key":"768_CR24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/15402002.2017.1357119","volume":"17","author":"PA Goodhines","year":"2019","unstructured":"Goodhines PA, Gellis LA, Kim J, Fucito LM, Park A. Self-medication for sleep in college students: concurrent and prospective associations with sleep and alcohol behavior. Behav Sleep Med. 2019;17(3):327\u201341.","journal-title":"Behav Sleep Med"},{"issue":"5 Suppl","key":"768_CR25","first-page":"S7","volume":"3","author":"T Roth","year":"2007","unstructured":"Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7\u201310.","journal-title":"J Clin Sleep Med"},{"issue":"2","key":"768_CR26","first-page":"101","volume":"25","author":"T Roehrs","year":"2001","unstructured":"Roehrs T, Roth T. Sleep, sleepiness, and alcohol use. Alcohol Res Health. 2001;25(2):101\u20139.","journal-title":"Alcohol Res Health"},{"issue":"2","key":"768_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1345\/aph.1R449","volume":"47","author":"J Ilomaki","year":"2013","unstructured":"Ilomaki J, Paljarvi T, Korhonen MJ, Enlund H, Alderman CP, Kauhanen J, et al. Prevalence of concomitant use of alcohol and sedative-hypnotic drugs in middle and older aged persons: a systematic review. Ann Pharmacother. 2013;47(2):257\u201368.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"768_CR28","first-page":"309","volume":"56","author":"CJ Wilkinson","year":"1995","unstructured":"Wilkinson CJ. The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. J Clin Psychiatry. 1995;56(7):309\u201318.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 2","key":"768_CR29","first-page":"115","volume":"5","author":"T Kuitunen","year":"1990","unstructured":"Kuitunen T, Mattila MJ, Seppala T. Actions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam and alcohol. Int Clin Psychopharmacol. 1990;5(Suppl 2):115\u201330.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"768_CR30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF00315578","volume":"38","author":"M Linnoila","year":"1990","unstructured":"Linnoila M, Stapleon JM, Lister R, Moss H, Lane E, Granger A, et al. Effects of adinazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. Eur J Clin Pharmacol. 1990;38(4):371\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"768_CR31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.1986.tb05175.x","volume":"21","author":"JM Scavone","year":"1986","unstructured":"Scavone JM, Greenblatt DJ, Harmatz JS, Shader RI. Kinetic and dynamic interaction of brotizolam and ethanol. Br J Clin Pharmacol. 1986;21(2):197\u2013204.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"768_CR32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/clpt.1985.88","volume":"37","author":"P Dorian","year":"1985","unstructured":"Dorian P, Sellers EM, Kaplan HL, Hamilton C, Greenblatt DJ, Abernethy D. Triazolam and ethanol interaction: kinetic and dynamic consequences. Clin Pharmacol Ther. 1985;37(5):558\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"768_CR33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.drugalcdep.2005.01.012","volume":"79","author":"I Kurzthaler","year":"2005","unstructured":"Kurzthaler I, Wambacher M, Golser K, Sperner G, Sperner-Unterweger B, Haidekker A, et al. Alcohol and benzodiazepines in falls: an epidemiological view. Drug Alcohol Depend. 2005;79(2):225\u201330.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"768_CR34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/hup.736","volume":"20","author":"I Kurzthaler","year":"2005","unstructured":"Kurzthaler I, Wambacher M, Golser K, Sperner G, Sperner-Unterweger B, Haidekker A, et al. Alcohol and\/or benzodiazepine use: different accidents\u2014different impacts? Hum Psychopharmacol. 2005;20(8):583\u20139.","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"768_CR35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/clpt.2011.3","volume":"89","author":"L Orriols","year":"2011","unstructured":"Orriols L, Philip P, Moore N, Castot A, Gadegbeku B, Delorme B, et al. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther. 2011;89(4):595\u2013601.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"768_CR36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/14728210903171948","volume":"14","author":"SS Sullivan","year":"2009","unstructured":"Sullivan SS, Guilleminault C. Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs. 2009;14(3):411\u201322.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"2","key":"768_CR37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/09540261.2014.888990","volume":"26","author":"DN Neubauer","year":"2014","unstructured":"Neubauer DN. New and emerging pharmacotherapeutic approaches for insomnia. Int Rev Psychiatry. 2014;26(2):214\u201324.","journal-title":"Int Rev Psychiatry"},{"issue":"5","key":"768_CR38","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2125.2008.03268.x","volume":"66","author":"RW Zoethout","year":"2008","unstructured":"Zoethout RW, van Gerven JM, Dumont GJ, Paltansing S, van Burgel ND, van der Linden M, et al. A comparative study of two methods for attaining constant alcohol levels. Br J Clin Pharmacol. 2008;66(5):674\u201381.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"768_CR39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2125.2009.03488.x","volume":"68","author":"RW Zoethout","year":"2009","unstructured":"Zoethout RW, Schoemaker RC, Zuurman L, van Pelt H, Dahan A, Cohen AF, et al. Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers. Br J Clin Pharmacol. 2009;68(4):524\u201334.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"768_CR40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0269881111431750","volume":"26","author":"ET te Beek","year":"2012","unstructured":"te Beek ET, Zoethout RW, Bani MS, Andorn A, Iavarone L, Klaassen ES, et al. Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state. J Psychopharmacol. 2012;26(2):303\u201314.","journal-title":"J Psychopharmacol."},{"key":"768_CR41","unstructured":"European Transport Safety Council (ETSC). Blood Alcohol Content (BAC) Drink Driving Limits across Europe. https:\/\/etsc.eu\/blood-alcohol-content-bac-drink-driving-limits-across-europe. Accessed 4 Dec 2019."},{"issue":"6","key":"768_CR42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/09687630600902477","volume":"13","author":"P Anderson","year":"2009","unstructured":"Anderson P, Baumberg B. Alcohol in Europe\u2014public health perspective: report summary. Drugs Educ Prev Policy. 2009;13(6):483\u20138.","journal-title":"Drugs Educ Prev Policy."},{"issue":"2","key":"768_CR43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.euroneuro.2012.04.012","volume":"23","author":"M Hoch","year":"2013","unstructured":"Hoch M, Hay JL, Hoever P, de Kam ML, te Beek ET, van Gerven JM, et al. Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans. Eur Neuropsychopharmacol. 2013;23(2):107\u201317.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"768_CR44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ajcn\/33.1.27","volume":"33","author":"PE Watson","year":"1980","unstructured":"Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr. 1980;33(1):27\u201339.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"768_CR45","first-page":"202","volume":"22","author":"S O\u2019Connor","year":"1998","unstructured":"O\u2019Connor S, Morzorati S, Christian J, Li TK. Clamping breath alcohol concentration reduces experimental variance: application to the study of acute tolerance to alcohol and alcohol elimination rate. Alcohol Clin Exp Res. 1998;22(1):202\u201310.","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"768_CR46","first-page":"94","volume":"28","author":"JA Mulder","year":"1991","unstructured":"Mulder JA, Neuteboom W, Wessel RM. Breath alcohol legislation in The Netherlands. Blutalkohol. 1991;28(2):94\u2013107.","journal-title":"Blutalkohol."},{"issue":"1","key":"768_CR47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/026988119901300102","volume":"13","author":"AL van Steveninck","year":"1999","unstructured":"van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol. 1999;13(1):10\u20137.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"768_CR48","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/0269881108089581","volume":"22","author":"L Zuurman","year":"2008","unstructured":"Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JC, et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol. 2008;22(7):707\u201316.","journal-title":"J Psychopharmacol"},{"issue":"Suppl 1","key":"768_CR49","doi-asserted-by":"crossref","first-page":"69S","DOI":"10.1111\/j.1365-2125.1984.tb02583.x","volume":"18","author":"RG Borland","year":"1984","unstructured":"Borland RG, Nicholson AN. Visual motor co-ordination and dynamic visual acuity. Br J Clin Pharmacol. 1984;18(Suppl 1):69S\u201372S.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"768_CR50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/clpt.2010.19","volume":"87","author":"P Hoever","year":"2010","unstructured":"Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther. 2010;87(5):593\u2013600.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"768_CR51","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1177\/0269881109106898","volume":"24","author":"SL de Haas","year":"2010","unstructured":"de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J. Pharmacokinetics, pharmacodynamics and the pharmacokinetic\/pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol. 2010;24(11):1619\u201329.","journal-title":"J Psychopharmacol"},{"issue":"Suppl","key":"768_CR52","first-page":"27","volume":"218","author":"BM Wright","year":"1971","unstructured":"Wright BM. A simple mechanical ataxia-meter. J Physiol. 1971;218(Suppl):27\u201328P.","journal-title":"J Physiol."},{"issue":"3","key":"768_CR53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","volume":"47","author":"A Bond","year":"1974","unstructured":"Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974;47(3):211\u20138.","journal-title":"Br J Med Psychol"},{"issue":"2","key":"768_CR54","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2001.01308.x","volume":"51","author":"SJ de Visser","year":"2001","unstructured":"de Visser SJ, van der Post J, Pieters MS, Cohen AF, van Gerven JM. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol. 2001;51(2):119\u201332.","journal-title":"Br J Clin Pharmacol"},{"issue":"21","key":"768_CR55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0028-3908(71)90039-6","volume":"10","author":"H Norris","year":"1971","unstructured":"Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology. 1971;10(21):181\u201391.","journal-title":"Neuropharmacology"},{"key":"768_CR56","volume-title":"Antiepileptic drugs: combination therapy and interactions","author":"BFD Bourgeois","year":"2005","unstructured":"Bourgeois BFD. Antiepileptic drugs: combination therapy and interactions. Cambridge: Cambridge University Press; 2005."},{"issue":"11","key":"768_CR57","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0269881115609015","volume":"29","author":"H Sun","year":"2015","unstructured":"Sun H, Yee KL, Gill S, Liu W, Li X, Panebianco D, et al. Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects. J Psychopharmacol. 2015;29(11):1159\u201369.","journal-title":"J Psychopharmacol"},{"issue":"6","key":"768_CR58","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/BF00210229","volume":"70","author":"A Pfeiffer","year":"1992","unstructured":"Pfeiffer A, Hogl B, Kaess H. Effect of ethanol and commonly ingested alcoholic beverages on gastric emptying and gastrointestinal transit. Clin Investig. 1992;70(6):487\u201391.","journal-title":"Clin Investig"},{"issue":"12","key":"768_CR59","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00535-013-0752-y","volume":"48","author":"A Kasicka-Jonderko","year":"2013","unstructured":"Kasicka-Jonderko A, Jonderko K, Bozek M, Kaminska M, Mglosiek P. Potent inhibitory effect of alcoholic beverages upon gastrointestinal passage of food and gallbladder emptying. J Gastroenterol. 2013;48(12):1311\u201323.","journal-title":"J Gastroenterol"},{"issue":"9","key":"768_CR60","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/BF01309614","volume":"26","author":"IT Beck","year":"1981","unstructured":"Beck IT, Dinda PK. Acute exposure of small intestine to ethanol: effects on morphology and function. Dig Dis Sci. 1981;26(9):817\u201338.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"768_CR61","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00426888","volume":"57","author":"DJ Greenblatt","year":"1978","unstructured":"Greenblatt DJ, Sahder RI, Weinberger DR, Allen MD, MacLaughlin DS. Effect of a cocktail on diazepam absorption. Psychopharmacology. 1978;57(2):199\u2013203.","journal-title":"Psychopharmacology"},{"issue":"10","key":"768_CR62","first-page":"426","volume":"28","author":"MI Morasso","year":"1990","unstructured":"Morasso MI, Chavez J, Gai MN, Arancibia A. Influence of alcohol consumption on erythromycin ethylsuccinate kinetics. Int J Clin Pharmacol Ther Toxicol. 1990;28(10):426\u20139.","journal-title":"Int J Clin Pharmacol Ther Toxicol."},{"issue":"1601","key":"768_CR63","first-page":"97","volume":"62","author":"The Medical Letter","year":"2020","unstructured":"The Medical Letter. Lemborexant (Dayvigo) for insomnia. Med Lett Drugs Ther. 2020;62(1601):97\u2013100.","journal-title":"Med Lett Drugs Ther"},{"issue":"8","key":"768_CR64","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/0269881112448946","volume":"26","author":"P Hoever","year":"2012","unstructured":"Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J. Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol. 2012;26(8):1071\u201380.","journal-title":"J Psychopharmacol"},{"key":"768_CR65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ddtec.2016.07.004","volume":"20","author":"GJ Groeneveld","year":"2016","unstructured":"Groeneveld GJ, Hay JL, Van Gerven JM. Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery. Drug Discov Today Technol. 2016;20:27\u201334.","journal-title":"Drug Discov Today Technol."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00768-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-020-00768-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00768-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:42:48Z","timestamp":1698367368000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-020-00768-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":65,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00768-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"assertion":[{"value":"23 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Idorsia Pharmaceuticals Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Benjamin Berger, Muriel Richard, Clemens Muehlan, and Jasper Dingemanse were full-time employees of Idorsia Pharmaceuticals Ltd at the time of study conduct. Muriel Richard, Clemens Muehlan, and Jasper Dingemanse own stocks in Idorsia Pharmaceuticals Ltd, and Clemens Muehlan and Jasper Dingemanse own stock options in Idorsia Pharmaceuticals Ltd. Sander Brooks and Rob Zuiker were employees of CHDR at the time of study conduct. There are no other relationships or activities that could appear to have influenced the submitted work. CHDR received financial compensation for conducting the study from Idorsia Pharmaceuticals Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study prior to any study-mandated procedure.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"MR and JD designed the study. BB and SB wrote the manuscript. SB and RZ performed the assessments and collected the data. Data were analyzed by BB, CM, SB, and RZ. All authors reviewed and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}